-
SAN DIEGO – April 10, 2017 – aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the appointment of Timothy P. Coughlin to its board of directors. Mr.
-
SAN DIEGO, April 3, 2017 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the appointment of Mr. Jeffrey S.
-
SAN DIEGO – Mar. 29, 2017 – aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the Company’s presentation at the Needham and Company 16 th Annual Healthcare
-
- Resolaris™, in multiple rare myopathy indications in four clinical trials in 2016, demonstrated signals of clinical activity and a favorable safety profile - - Advancing second program, Stalaris™, for rare lung indications into a first in human clinical trial in 2H17 - - Closing in on third
-
- Estate Covers over 175 Patents for Physiocrine Biology, a New Class of Potential Targets and Therapeutics - - Over 100 Patents Issued or Allowed in the Past 12 Months - SAN DIEGO , March 15, 2017 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the
-
SAN DIEGO , March 3, 2017 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that the European Medicines Agency (EMA) has granted orphan drug
-
SAN DIEGO , March 1, 2017 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the Company's presentation at the Cowen and Company 37 th Annual
-
SAN DIEGO , Feb. 28, 2017 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that its product candidate Resolaris™ was granted Orphan Drug
-
- First Reported Fast Track Designation for LGMD2B Treatment - SAN DIEGO , Jan. 18, 2017 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today
-
SAN DIEGO , Jan. 4, 2017 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the Company's participation at the 35 th Annual J.P.